Decision on voluntary liquidation 
The extra general meeting adopted the proposal from the board of directors and thus resolved that the Company should enter into voluntary liquidation in accordance with Chapter 25, Section 3 of the Swedish Companies Act. 

Liquidation date
The resolution regarding liquidation will take effect from the date when the Swedish Companies Registration Office (Sw Bolagsverket) appoints a liquidator.

Estimated distribution date
The distribution of any liquidation proceeds will take place after the notice period for unknown creditors has expired, or - at the latest - in conjunction with the presentation of the liquidator's final report. The board of directors finds it challenging to provide anything more than a rough estimate regarding the distribution date, but, hopefully the distribution can take place during the third or fourth quarter of 2024.

Estimated distribution amount
The board's preliminary assessment is that the potential distribution to shareholders will amount to maximum SEK 5 million. However, also in this case, it is difficult to predict the size of the distribution amount, as it depends on both the costs associated with the business and liquidation process up to the distribution date, and the proceeds from the sale of the Company's assets.

Proposed liquidator 
Olov Kling, lawyer at Advokatfirman Lindahl, was proposed as liquidator.

Information to shareholders during the liquidation process
Information and announcements regarding the liquidation process will be published on the Company's website www.bioservo.com.

For more information, please contact
Petter Bäckgren, CEO, Bioservo Technologies AB
Phone: +468 21 17 10
petter.backgren@bioservo.com  (petter.backgren@bioservo.com )

Mikael Wester, Marketing Director, Bioservo Technologies AB
Phone: +468 21 17 10
mikael.wester@bioservo.com

About Bioservo Technologies
Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy and efficient. The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength. Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Kista north of Stockholm.

FNCA Sweden AB is the company's Certified Adviser on Nasdaq First North Growth Market.
For more information, please visit www.bioservo.com